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Abstract
Betulin is a triterpene class natural product present, for example, in the outer layer of birch 
bark, which is a low-value waste product of the forestry industry in Northern Hemisphere. 
Oxidation products of betulin, namely betulinic acid and betulonic acid, have been shown 
to have several biological activities. This makes betulin an interesting starting point for 
drug discovery projects.
In this work, mainly ring A-fused heterocyclic derivatives of betulin were synthesized, 
and their structure-activity relationships against a protozoan parasite Leishmania
donovani, prostate cancer cell lines, a serine hydrolase enzyme (ABHD12), and 
inflammatory factors were studied. The heterocycles used included pyridine, pyrazine, 
pyrazole, indole, isoxazole, and oxazole rings. Also, positions C-28 and C-20 of these 
compounds were modified and the resulting structure-activity relationships (SAR) were 
studied.
Among the tested compounds, two heterocyclic betulin derivatives showed significant 
inhibition against L. donovani amastigotes growth. These compounds showed improved 
activity compared to the heterocyclic betulin derivatives tested previously. Also, a betulin-
derived potent anti-HIV compound, bevirimat, showed L. donovani growth inhibition at a
similar level to the ring A-fused heterocyclic betulin derivatives. However, further 
optimization is needed to get more potent betulin derivative activity against L. donovani.
In prostate cancer studies some of the betulin derivatives displayed dose-dependent 
anti-invasive activity at nanomolar concentrations with negligible cytotoxicity. The most 
potent compounds were betulin derivatives with a ring A-fused heterocycle. Also, the
carboxyl group at C-28 seemed to be important for activity. These compounds showed 
considerably improved anti-invasive effects compared to betulinic acid.
Betulin derivatives were found to selectively inhibit the ABHD12 serine hydrolase 
enzyme without inhibiting other endocannabinoid hydrolases and without activity towards 
cannabinoid receptors. In mechanistic studies, the inhibition type was shown to be 
reversible. Important structural features required for ABHD12 inhibition were revealed 
based on our SAR studies.
Heterocyclic betulin derivatives were shown to suppress the expression of several 
inflammation mediators, such as iNOS, IL-6, and MCP-1, a pyrazole derivative being the 
most potent compound. With further improvement and development, more potent betulin 
derivatives could be found.
The betulin derivatives show different activity with different targets, which means they 
are selective. Selectivity and potency could be further improved to obtain a potential 
betulin-derived compound for further development. In this work, betulin has been shown 
to be a good starting point for several different drug discovery projects.
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2-AG 2-arachidonoylglycerol
2D two dimensional
3D three dimensional
ABHD12 serine hydrolase ?/?-hydrolase domain containing 12 gene
ABHD6 serine hydrolase ?/?-hydrolase domain containing 6 gene
Ac acetyl
Bcl-2 B-cell lymphoma 2
Bn benzyl
Bz benzoyl
CB1 cannabinoid receptor type 1
CB2 cannabinoid receptor type 2
COX-2 cyclooxygenase-2
DCM dichloromethane
DIPEA N,N-diisopropylethylamine
DMF N,N-dimethylformamide
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
FAAH fatty acid amide hydrolase
hABHD12 human serine hydrolase ?/?-hydrolase domain containing 12 gene
HIV human immunodeficiency virus
HNE human neutrophil elastase
IBX 2-iodoxybenzoic acid
IFN-? interferon-?
IL-6 interleukin-6
IL-8 interleukin-8
iNOS inducible nitric oxide synthase
LPS lysophosphatidylserine 
MAGL monoacylglycerol lipase
MAPK mitogen-activated protein kinase
MCP-1 monocyte chemotactic protein-1
mPGES-1 microsomal prostaglandin E2 synthase-1
mRNA messenger ribonucleic acid
NF-?B nuclear factor kappa B
NSAID nonsteroidal anti-inflammatory drug
NO nitric oxide
PCC pyridinium chlorochromate
PGE2 prostaglandin E2
Ph phenyl
PHARC polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, cataract –disorder
p-TsOH para-toluenesulfonic acid
rt room temperature
SAG sodium antimony gluconate
xi
SAR structure-activity relationship
t-Bu tert-butyl
TFAA trifluoroacetic acid anhydride
THF tetrahydrofuran
THL tetrahydrolipstatin
THP tetrahydropyranyl
TNF-? tumor necrosis factor ?
TPA 12-O-tetradecanoylphorbol-13-acetate
Table 1. The cell lines mentioned in this work.
Type Cell line
Glia C6 (rat)
Kidney HEK-293 (human)
Leukemia CEM (human)
Lung A549 (human)
Macrophages THP-1 (human), J774, RAW264.7 (murine)
Melanoma MEL-1, MEL-2, MEL-4 (human)
Prostate Ep156T, LNCaP, PC-3 (human)

11 Introduction
Natural products have been used as medicines for thousands of years, and they still play an 
important role in modern drug discovery.1,2 During a thirty-year period, from 1981 to 
2010, 64% of small-molecule approved drugs were natural products, their semisynthetic 
derivatives or synthetic natural product mimics and analogs.
Triterpenes are secondary metabolites found all over the plant kingdom.3 They are 
synthesized in plants by the cyclization of squalene, which contains six isoprene units.
Over 20,000 triterpenes, occurring in their free form or as glycosides (saponins, in other 
words) have been isolated so far. Tetracyclic and pentacyclic triterpenes are the most 
abundant triterpenes. Pentacyclic triterpenes are divided into groups based on the chemical 
structures of their carbon skeletons; gammaceranes, hopanes, lupanes, oleananes, and 
ursanes, to name just a few. They can be found in higher concentrations in bark; in the 
waxy covering of leaves; or in peel. Triterpenoids show activity with several different 
biological targets.
Betulin (1, Figure 1) is a triterpenoid of the lupane series, and it can be isolated from 
the bark of white birches (Betula spp.) in approximately 30% yield of dry weight.4 Birch 
bark is a low-value waste product of the forestry industry in the Northern Hemisphere. 
Many [bio]synthetic oxidation products of betulin such as betulinic acid (2) and betulonic 
acid (3) have several pharmacological properties. They have shown antiviral5 (including
anti-HIV6), anti-inflammatory7, anti-malarial8, anti-leishmanial9, and anti-tumoral10
effects, among others. Betulin (1) can easily be modified at the C-3 secondary hydroxy 
group, C-20 double bond, and C-28 primary hydroxy group. These functionalities can be
utilized to synthesize more active and specific betulin derivatives. In the following review 
of the literature only selected triterpenoid derivatives against cancer, inflammation, and 
leishmaniasis are covered.
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Structures of betulin 1, betulinic acid 2, and betulonic acid 3.Figure 1
22 Review of the literature
2.1 Triterpenoids against leishmaniasis
Leishmaniasis is a tropical disease caused by the protozoan Leishmania parasites, which 
are transmitted by the bite of infected sandflies.11 There are over twenty Leishmania
species causing leishmaniasis. The main forms of the disease are visceral, cutaneous, and 
mucocutaneous leishmaniasis. The visceral form is fatal if not treated; the cutaneous form 
causes skin lesions leading to scars and disability; and the mucocutaneous form destroys 
the mucous membrane of the nose, mouth, and throat. There are 310 million people living 
in areas at risk of infection. It has been estimated that there are 1.3 million new cases and 
30 000 deaths annually caused by leishmaniasis. The current treatments have severe 
adverse effects, require hospitalization, or are highly expensive. Resistance is also a 
problem in some areas. One treatment does not work for all forms of the disease and 
species of leishmaniasis. Encouragingly, some new compounds have been shown to be 
selectively active against some Leishmania species.
Anti-leishmanial activity of betulinic aldehyde in vitro was first reported against 
Leishmania amazonensis.12 Oleanolic acid (4) and ursolic acid (5, Figure 2) showed in 
vitro activity against L. donovani, L. major, and L. amazonensis promastigotes and 
amastigotes, i.e. extra- and intracellular forms13,14 However, they showed cytotoxicity 
towards non-parasitized macrophage-like RAW 264.7 cells and mouse peritoneal 
macrophages as well, which limits their use as anti-leishmanial compounds. In another 
study, oleanolic acid (4) and maslinic acid (6) showed activity against L. infantum and L. 
amazonensis promastigotes in vitro.15 Triterpenoids with a hydroxy group at C-2 were as 
active against L. amazonensis promastigotes as the parent oleanolic (4) and ursolic (5)
acids.14 On the other hand, they showed no activity against amastigotes. Oleanolic acid (4)
was more active in vitro against L. donovani promastigotes than the corresponding C-3
methyl ether.16 BALB/c mice infected with L. donovani were cured of their parasite 
burden with 18?-glycyrrhetinic acid (7).17 L. donovani infection in BALB/c mice differs 
from the infection in humans, being just chronic rather than fatal, and decrease in the 
parasite burden is part of the course of the infection. Nevertheless, these authors consider
that this is a good experimental model for the disease. Combination therapy with sodium 
antimony gluconate (SAG) and glycyrrhizinic acid inhibited SAG-resistant Leishmania
infection in a synergistic manner.18
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Structures of oleanolic acid (4), ursolic acid (5), maslinic acid (6) ???????-Figure 2
glycyrrhetinic acid (7).
3Maytenin (8) and pristimerin (9, Figure 3) showed potent activity against L. amazonensis
and L. chagasi promastigotes in vitro (0.09 nM and 0.05 nM for L. amazonensis, and 0.46 
nM and 0.41 nM for L. chagasi, respectively).19 These compounds are very potent, since
the positive control pentamidine showed IC50 values of 6.8 nM for L. amazonensis, and 
4.0 nM for L. chagasi.
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Structures of maytenin 8 and pristimerin 9.Figure 3
Triterpenoid saponins with an oleanane skeleton extracted from Maesa balansae Mez20,
and with a hederin skeleton isolated from ivy (Hedera helix L.)21, showed nanomolar anti-
leishmanial activity in vitro on L. infantum. Oleanane saponins were also effective against 
L. donovani in vitro.22 Both the ester and sugar moiety seemed to be important for activity 
(Figure 4).23 In hamsters, the oleanane saponin showed similar potency to liposomal 
amphotericin B, which is used as a first line treatment for leishmaniasis.24 Also, the
triterpenoid saponin, arborenin, isolated from an Indian tree Careya arborea Roxb. 
showed in vitro activity against L. donovani.25
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Structure of an oleanane saponin extracted from Maesa balansae Mez with IC50 value Figure 4
of 0.013 nM against Leishmania infantum amastigotes in vitro.23
The bark of cork oak (Quercus suber L.) is an abundant source of cork for industry.26 As a 
by-product of making corkboard, the so-called black wax is obtained with no current 
practical or economic use. Friedelane triterpenes were extracted from it and their 
derivatives were synthesized. Some of them showed activity against L. infantum.
Dihydrobetulinic acid has been shown to cause apoptosis in Leishmania donovani
promastigotes and amastigotes by inhibiting DNA topoisomerases.27 Adding different 
ester groups at the C-28 position of betulinic acid (2)28, betulin (1) or dihydrobetulin29
4improved the anti-leishmanial activity. The presence of a carbonyl group at C-3 and a
carboxyl group at C-28 seemed important for activity.28 Esterification or oxidation of C-3
hydroxy group of betulinic acid increased potency against L. amazonensis, whereas these 
modifications did not make any difference in potency against L. braziliensis.30 On the 
other hand, betulinic acid methyl ester showed improved activity against L. braziliensis 
compared to betulinic acid (2). Heterocycloadducts of betulin (10a and 11) showed better 
inhibition than betulin (1) with L. infantum and L. donovani (Figure 5).9,31 Compound 10b
showed the best inhibition with L. braziliensis.32
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11
The most active heterocycloadduct compounds against L. donovani (10a, IC50 9 μM),Figure 5
L. braziliensis (10b, IC50 0.3 μM) and L. infantum (11).9,31
Modification at C-20 appeared to improve anti-leishmanial activity of betulin derivatives 
(Figure 6).33 However, imidazole derivative of betulonic acid (13) showed better activity.
Combining betulin or betulinic acid derivative treatment with approved leishmaniasis 
medication, miltefosine had a synergistic effect, as IC50 values were smaller than for the 
compounds alone. Combination treatment could be a new solution for combating the
developing drug resistance.
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The most active betulin (12) and betulinic acid (13) derivatives against L. infantum.33Figure 6
Based on activity studies of a series of tirucallane triterpenoids, it was concluded that the 
C-3 hydroxy group and a double bond at C-24/C-25 with the carboxyl group at C-27 are 
crucial features for antileishmanial activity against L. infantum (Figure 7).34 The natural 
product tirucallane (14) was more effective than its semisynthetic derivatives. Among a 
set of tetracyclic triterpenoids, compounds with ketone or hydroxy groups at C-3, C-7, and 
C-11 showed higher activity against L. infantum promastigotes in vitro (Figure 7,
compound 15).35
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The structures of the representative tirucallane (14), and friedelane derivative (15)Figure 7
with their IC50 values against L. infantum promastigotes.34,35
In summary, hydrogen bond forming groups such as carbonyl or hydroxy in triterpenoid 
structure appear to be beneficial for anti-leishmanial activity. Many natural products are 
more active than their semisynthetic derivatives. Surprisingly, further development of 
some highly active natural products have not been reported. In the absence of an extensive 
SAR study, including bioisosteres of seemingly important groups, further conclusions 
about SARs are hard to draw. Since there are so many forms of the disease and species of 
Leishmania parasites, in addition to the parasite’s complex life cycle, leishmaniasis is a 
highly challenging target to tackle and more research on it is needed.
2.2 Pentacyclic triterpenoids against cancer
The anti-tumoral and cytotoxic properties of betulin (1) and betulinic acid (2) were already 
known some forty years ago.36–38 Extensive studies started after finding that betulinic acid 
(2) induces apoptosis in human melanoma cells (MEL-2) without toxicity.10 Initially,
betulinic acid (2) was thought to be selectively cytotoxic only towards melanoma cells. 
However, when a different set of cancer cell lines was used, betulinic acid derivatives also 
displayed cytotoxicity towards them.39 Thus far several cancer lines have been shown to 
be sensitive not only to betulinic acid (2), but also to other pentacyclic triterpenoids.40
They show cytotoxicity with non-cancerous cells as well, but those tolerate much higher 
triterpenoid concentrations than cancer cells from the same origin.41 Triterpenoids induce 
apoptosis via several different mechanisms, as extensively described in literature.40,42–44
For example, betulinic acid (2) induces apoptosis by direct mitochondrial perturbations;
by modulating expression levels of Bcl-2 family proteins; and by inducing NF-?B (nuclear 
factor kappa B) activation, to mention just a few of them.
Now we turn to the effects of the modifications at different positions of the pentacyclic 
triterpene skeleton. Since dozens of different cancer cell lines have been assayed in many 
studies, only the generally most promising activities are reviewed here without detailed 
lists of the cell lines used. It should also be noted that due the variation of experimental 
conditions from study to study, results are not entirely comparable to each other.
The double bond at C-20 was shown not to be important for cytotoxic activity (Figure 
8).45,46 In fact, when the double bond at C-20 was reduced, activity was further 
improved.39 Modifying the C-20 double bond into a ketone, hydroxy or oxime group 
resulted in loss of activity.39 In another study, compounds having the reduced C-20 double 
bond in the presence of C-3 oxime (16a) or phenylhydrazone (16b) moieties showed 
6increased activity against some of the cell lines tested, compared to the corresponding 
derivatives possessing the double bond (17a and 17b, respectively, Figure 8).45 A
phenylhydrazone or oxime group at C-3, and a 20,29-dihydro moiety seemed to be 
important for cytotoxicity towards prostate and ovarian, or lung cancer cell lines.47 In a set 
of ring E-modified oxidation products cytotoxic activity was related to the presence of the 
?-dicarbonyl group (18 and 19) or an ?-unsaturated ketone/aldehyde moiety (20) in their 
structures (Figure 9).48
Comparison of cytotoxicity of the C-19 isopropenyl and isopropyl derivatives of Figure 8
betulonic acid against prostate, lung, and ovarian cancer cell lines.45
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Representative ring E-oxidized betulin derivatives possessing a ?-dicarbonyl group Figure 9
(18 and 19) or an ?-unsaturated ketone/aldehyde (20) moiety.48
Converting the C-3 hydroxy group of betulinic acid (2) into a ketone increased the
cytotoxicity towards several cancer cell lines.39,45,47,49,50 On the other hand, betulonic acid 
(3) was less active than betulinic acid (2) on some other cell lines.45 In general, the C-3
hydroxy group does not seem to be essential for cytotoxicity.46 Derivatives of the 
pentacyclic triterpenoid ursolic acid with a 3?-orientated hydroxy group were more 
cytotoxic than the corresponding ?-diastereomer.51 Adding a 3?-amino group improved 
cytotoxicity further. Derivatizing the C-3 hydroxy group of betulinic acid (2) with a
phthaloyl52, (1H-1,2,4-triazolecarbonyl)oxy28 or 1H-imidazole-1-carboxylate53,54 group led 
to higher cytotoxic activity compared to betulinic acid (2) (Figure 10; compounds 21 - 23,
respectively). The 3-aza derivatives of betulin (24) and betulinic acid showed improved 
cytotoxicity compared to betulinic acid (2).55
Compound R ED50 (μM)
16a OH 0.7 - 3
16b NH-Ph 0.4 - 6
17a OH 2 - 10
17b NH-Ph 2 - 10
COOH
N
R
COOH
N
R
17a-17b16a-16b
7The structurally-related glycyrrhetinic acid derivatives possessing a benzyl ether 
substituent at C-3 (25) showed improved cytotoxicity compared to glycyrrhetinic acid, and 
caused cell death via apoptosis.56 Betulinic acid derivatives having C-3 ethyl carbamates 
showed higher cytotoxicity than phenyl carbamates.57 Compounds possessing an alkyl 
ester group at C-3 showed only moderate activity, whereas an ester with a chloroacetyl 
side chain (26) was a more potent cytotoxic compound than the alkyl ester substituted 
ones.58 Interestingly, betulin derivatives with glyceryl esters linked to C-3 showed lower 
cytotoxic activity than betulin (1).59
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Representative compounds with different variations at C-3 and their IC50 values from Figure 10
cytotoxicity studies towards leukemia, melanoma, colon cancer and prostate cancer
cell lines.52–56,58
Betulinic acid60 and ursolic acid51,61,62 derivatives possessing a 3-O-acetyl moiety had 
improved cytotoxic activity compared to the parent compounds. On the other hand, 3?-
hydroxy-21-ketone (27) was more active than 3?-acetoxy-21-ketone (28), whereas 3?-
acetoxy-21,22-dione (29) was more active than its deacetylated counterpart (30, Figure 
11).63
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??-Hydroxy-21-ketone (27), ??-acetoxy-21-ketone (28), ??-acetoxy-21,22-dione (29)Figure 11
and ??-hydroxy-21,22-dione (30) and their IC50 values towards leukemia, melanoma, 
colon and prostate cancer cell lines.63
Ring A-fused heterocyclic betulin and allobetulin derivatives showed decreased 
cytotoxicity, and the authors presume it is due to their poor aqueous solubility and 
resulting bioavailability.64 However, ring A-fused pyrazine derivative showed cytotoxic 
activity against several cancer cell lines.65 Interestingly, when a pyrazine ring was fused to 
ring E or five-membered ring A, the resulting compounds were inactive. Adding a cyano-
enone moiety to ring A of the 18?-glycyrrhetinic acid derivative (31) improved 
antiproliferative activity against leukemia cells compared to the parent compound (Figure 
12).66 Also, oleanolic acid derivatives with a cyano-enone-bearing ring A (32) have shown 
potency against lung cancer67 and leukemia68. The methyl ester of compound 32 induces 
apoptosis of cancer cells and has been tested in Phase II clinical trials.69,70 Compounds 
with a lupane skeleton possessing an electron-withdrawing group at C-2 showed improved 
activity against human melanoma.71 Lupane derivatives with a C-2 methylene group and a
C-28 carbonyl showed good cytotoxicity towards several cancer cell lines.72
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Structures of the ???-glycyrrhetinic acid derivative 31 and oleanolic acid derivative Figure 12
32, and their IC50 values towards a myelocytic leukemia cell line.66,68
It has been shown in several studies that a protonated carboxyl group at C-28 is important 
for cytotoxic activity against several cancer cell lines.45,46,49,53,71,73–75 In some studies, it 
has been concluded that a hydrogen bond donor is important at C-28 for cytotoxic 
activity.49,51 However, others have shown that it is the C-28 carbonyl group that is
necessary for cytotoxicity.46,51,75,76 When azidothymidine was linked via a triazole ring to 
9a C-28 ester (33) or amide (34), triterpenoids showed good to moderate cytotoxic activity, 
respectively (Figure 13).77,78 It is noteworthy that these hybrid compounds displayed more 
potent cytotoxic activity than either of the parent compounds, betulinic acid (2) or 
azidothymidine, alone.
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Representative azidothymidine derivatives of betulinic acid and their IC50 values Figure 13
towards cervical cancer cell lines. 77,78
C-28 glycidic amide and ?-ketoesters were more potent than betulinic acid (2).60 Results 
were in line with the assumption that a C-28 carbonyl group is important for the activity. 
Betulonic aldehyde derivatives with triazole or pyrazole moieties attached to the C-28 
carbonyl showed selective cytotoxicity towards colon cancer and breast cancer cells.79
Betulinic acid saponin bearing L-rhamnose sugars at C-3 and C-28 showed higher
cytotoxicity (1.3-1.9 μM) compared to betulinic acid (2).80 On the other hand, compounds 
having a glyceryl unit at C-28 were as potent as betulinic acid (2).59
Compound 35 (Figure 14), with an elongated C-17 side chain, was more active than 
the corresponding compound with a C-3 hydroxyl, namely ichopanic acid.81 Ichopanic 
acid was more active than betulinic acid (2). Other compounds with elongated C-17 side 
chains were cytotoxic only when a primary hydroxy group was present at C-28a.
Surprisingly, coupling L-rhamnose to C-28a (36) resulted in decreased cytotoxicity. 
Compounds possessing a short alkynyl chain linked to C-28 with ester (37) or carbonate 
groups showed strong cytotoxicity against human leukemia.82 In addition, compounds 
with an alkynyl side chain with a pyrrolidine moiety as a small terminal tertiary amino
moiety directly attached to C-28 (38) showed increased cytotoxicity compared to betulinic 
acid (2).83
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Representative C-28 modified betulin derivatives and their IC50 values towards Figure 14
leukemia, ovarian, breast, and colon cancer cell lines.81–83
An ethynyl side chain at C-28 showed very promising antitumor activity by triggering 
apoptosis.79 Betulin derivatives with an acetylenic side chain at C-28 showed improved 
cytotoxicity compared to betulinic acid (2).74 In a set of different C-28 ester derivatives of 
betulinic acid, the acetoxymethyl ester derivative (39) showed similar cytotoxic activity to 
the parent acid whereas other esters were inactive (Figure 15).84 Ester derivatives with a
vicinal dicarbonyl system conjugated in its enol form on ring A (40) were the most active 
compounds. It was concluded that modifications of ring A are more efficient than ester
modifications at C-28.
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39 40
IC50 12-29 μM IC50 6-60 μM
Representative acetoxymethyl ester (39) and dicarbonyl (conjugated enol form) (40)Figure 15
derivatives of betulinic acid with their IC50 values from cytotoxicity studies towards
leukemia, prostate, lung, and breast cancer cell lines.84
Triterpenoids have obvious and general water solubility problems that are likely to lead to 
a low bioavailability of the compounds. To improve the aqueous solubility and 
bioavailability of betulin derivatives, some of them have been encapsulated with soybean 
lecithin, resulting in increased cytotoxicity.72,74,79 Betulinic acid derivatives with an amino 
acid conjugated to C-28 showed selective cytotoxicity on melanoma cells and remarkably
improved aqueous solubility.85 In a set of ursolic acid derivatives, more lipophilic 
compounds showed higher cytotoxicity, which might be due to their better membrane 
permeability.62
To summarize: the pentacyclic triterpene skeleton can be modified at many different 
positions in order to obtain more cytotoxic compounds towards various cancer cell lines. 
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Cytotoxic activity of betulin-derived triterpenoids is typically more related to the 
electronic and hydrogen bond-forming properties than to the size of the substituents. In 
many studies, the sets of the compounds tested were quite small, so further conclusions
concerning structure-activity relationships are challenging to draw based on those results.
To be certain about the importance of the presence of a particular group, corresponding 
bioisosteres should be synthesized and tested as well. In mechanistic studies, several 
mechanisms of action have been found.86,87 One compound can act via several 
mechanisms, which makes further development into a potential lead compound harder.
2.3 Triterpenoids as analgesics and anti-inflammatory agents
The function of inflammation is to repair damage or an infection, and thus return the 
organism back to homeostasis.88 However, if inflammation prolongs, it can cause damage 
to the organism. Chronic inflammation is known to lead to cancer development. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to delay the 
development of premalignant tumors in some instances.89 The inflammation cascade is 
very complex and involves many different classes of mediators.88 Inducible nitric oxide 
synthase (iNOS) and inducible cyclooxygenase (COX-2) are some of the enzymes 
responsible for the inflammatory response. Excessive expression of iNOS or COX-2 have 
been associated with many diseases, such as neurodegenerative diseases90,91 and 
rheumatoid arthritis92, as well as carcinogenesis93. Natural triterpenoids have been shown 
to inhibit inflammation94–96 and later on they were shown to hinder the expression of pro-
inflammatory mediators, the production of secondary messengers, and expression of 
transcription factors.88
Betulinic acid (2) has shown inhibition of carrageenan and serotonin-induced rat paw 
edema, which demonstrates anti-inflammatory properties.7 Betulin (1) has also been 
shown to reduce acute LPS (lysophosphatidylserine)-induced lung injury.97 Based on a set 
of natural triterpenoids, it was concluded that a carboxyl group at C-28 or C-30 increases 
the inhibition of carrageenan paw and TPA (12-O-tetradecanoylphorbol-13-acetate) ear 
edema.98 ?????????????? ??? ?- ???? ?-amyrin ester derivatives were tested on an acetic 
acid-induced visceral pain model, propionate (41), hexanoate (42), and octanoate (43)
derivatives showed very good antinociceptive activity, compound 43 being the best of the 
tested compounds (Figure 16).99
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41 R = CH3CH2 ID50 0.87 μmol/kg
42 R = CH3(CH2)3CH2 ID50 1.04 μmol/kg
43 R = CH3(CH2)5CH2 ID50 0.0055 μmol/kg
?-amyrin derivatives ?-amyrin derivatives
The most activ???- ?????-amyrin derivatives against acetic acid-induced visceral Figure 16
pain.99
In a set of oleanolic (4) and ursolic acid (5) derivatives (Figure 17), the ring A enones 
were found to be crucial for inhibition of iNOS and COX-2 mRNA (messenger 
ribonucleic acid) expression.100,101 The presence of a carbonyl group at C-11 or C-12 of 
ring C seemed important for the activity. Addition of an ?-double bond (44 and 45)
enhanced inhibitory activity further (Figure 17). Compounds with a hydrophilic group at 
C-28 were more active than compounds with hydrophobic groups. Compounds with an 
oleanane skeleton were found to show higher inhibition than compounds with an ursane 
skeleton (46). In further studies, a C-2 nitrile group (compound 32) was found to further 
improve the inhibition of NO production induced by IFN-? (interferon-?) in mouse 
macrophages.102 A methyl ester of 32 has been shown to suppress inflammatory signals in 
cancer and immune cells.103 It has been concluded that electron-withdrawing groups at C-
2 increase potency, whereas electron-releasing groups decrease potency.102 According to a 
structure-activity study of hundreds of synthetic oleanane triterpenoids, the ring A enone
unit is critical for maximum inhibition of iNOS induction.104 Expansion, opening, and 
heterocycle installation at ring A decreases activity. The presence of ester and amide
groups at C-28 results in excellent activity; and a cyano group at C-28 leads to picomolar
inhibitory activity of induced iNOS expression.
COOH
O 45
O
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COOH
O 44
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O 32
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Toxic
NC
COOH
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Structures of oleanolic and ursolic acid (4 and 5), and their representative derivatives Figure 17
(44-46 and 32) with their IC50 values for inhibition of IFN-?-induced NO production 
in mouse macrophages.100,102
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Methyl 3-octanoyloxyiminoolean-12-en-28-oate (47) showed analgesic activity at high 
doses (300 mg/kg) and an anti-inflammatory effect comparable to the effect of diclofenac 
on carrageenan-induced edema (Figure 18).105 Compound 47 showed a synergistic 
analgesic effect with morphine and a synergistic anti-inflammatory effect with diclofenac.
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47
Structure of methyl 3-octanoyloxyiminoolean-12-en-28-oate (47).105Figure 18
Pentacyclic triterpenoids, oleanolic acid (4), ursolic acid (5), glycyrrhetinic acid (7),
glycyrrhizin, betulinic acid (2) and lupeol were shown to inhibit human neutrophil elastase 
(HNE), which assists neutrophil migration to inflammation sites.106 Ursolic acid (5)
showed the most potent inhibitory activity with an IC50 value of 5.5 μM. Interestingly, the 
tetracyclic triterpenoids tested showed only minor inhibition. Based on the in vitro and 
docking studies, a C-28 carboxyl group and double bond at C-12 increased the inhibitory 
activity.
Triterpenoids present in apple peel, such as betulinic acid (2), oleanolic acid (4), 
ursolic acid (5), corosolic acid and maslinic acid (6) have shown anti-inflammatory 
activity.107 Lanostane triterpenoids 48-54 showed anti-inflammatory activity by inducing 
heme oxygenase protein expression, which is associated with anti-inflammatory responses 
in RAW264.7 cells (Figure 19).108
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Lanostane triterpenoids with anti-inflammatory activity.108Figure 19
Ursolic acid (5) and methyl ursolate showed significant reduction of carrageenan-induced 
paw edema.109 Betulinic acid-peptide conjugates containing histidine, alanine, tryptophan 
and isoleucine amino acid fragments showed anti-inflammatory activity comparable to
that of indomethacin.110 Pristimerin (9) has been shown to inhibit LPS-induced TNF-? and 
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IL-8 production.111 Oleanane and ursane-type natural compounds 55-58 showed moderate 
inhibition of LPS-induced NO production (Figure 20).112
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57 58
The oleanane and ursane type natural compounds with their IC50 values against LPS-Figure 20
induced NO production.112
A set of triterpene carboxylic acids were tested as inhibitors of microsomal prostaglandin
E2 synthase (mPGES-1), which is an inducible pro-inflammatory enzyme.113 Tirucallic 
acids showed the best IC50 values (Figure 21). Acetylation of the C-3 hydroxy group 
improved activity (compounds 59 and 60). Neither converting the C-3 hydroxy group into 
ketone (compound 61) nor changing 3?- configuration of the hydroxy group to 3?-
(compound 62) improved the activity. Among the roburic acids, a ketone (64) showed 
mPGES-1 inhibition while roburic acids devoid of it showed no activity (IC50 >10 μM).
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Representative tirucallic acids (59-63) and a roburic acid derivative (64) with their Figure 21
IC50 values for inhibition of mPGES-1 activity.113
The bark, leaves and flowers of a Thai plant use in herbal medicine, Hiptage benghalensis
(L.) Kurz, have traditionally been used to treat wounds, ulcers and asthma among other 
ailments. Triterpenes 65-67 (Figure 22) isolated from this plant were shown to suppress 
NO and PGE2 production, and iNOS and COX-2 expression in LPS-induced RAW 264.7 
macrophages through NF-?B suppression.114
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Triterpenes isolated from Hiptage benghalensis and their IC50 values against LPS-Figure 22
induced NO production in RAW 264.7 macrophages.114
Triterpenes showing activity against cannabinoid receptor mediated 
pain and inflammation
Two types of cannabinoid receptors have been identified so far, namely cannabinoid 1 
(CB1) and cannabinoid 2 (CB2).115 The CB1 receptors are distributed in the peripheral and 
central nervous system, and CB2 receptors are mainly found in immune and hematopoietic 
system. Many cannabinoid receptor agonists have been shown to reduce inflammation and
neuropathic pain.116 The first endogenous ligands, or endocannabinoids, discovered were 
anandamide and 2-arachidonoylglycerol (2-AG).115 2-AG is metabolized by serine 
hydrolase enzymes monoacylglycerol lipase (MAGL) and ?/?-hydrolases 6 (ABHD6) and 
12 (ABHD12). Signaling system of these endocannabinoids has been shown to participate 
in many dysfunctions, such as pain, inflammation, immunological disorders, obesity and 
cancer.117
Betulinic acid (2) has been shown to bind to CB1 and CB2 receptors; it can inhibit
breast cancer growth via this pathway.118 ?- and ?-amyrin (Figure 23, 68 and 69
respectively) have been shown to reduce chronic and inflammatory pain directly via CB1 
and CB2 receptors.116 Later on, ?- and ?-amyrin were found to selectively modulate CB1 
receptor activation and down-regulate endocannabinoid hydrolases.119 Anti-inflammatory 
and anti-neuropathic hyperalgesia effects of euphol (70) depend partly on its interactions 
with cannabinoid receptors.120 Interestingly, despite these antinociceptive effects, euphol 
(70) does not show any psychomodulatory effects in the central nervous system, even at 
high doses. Pristimerin (9), euphol (70), and ?-amyrin (69) have been reported to suppress
2-AG hydrolysis by inhibiting MAGL activity (IC50 = 93 nM, 315 nM, and 2.8 μM
respectively). 121,122 Celastrol (71) has been shown to cause analgesia through CB2 
signaling.
HO68
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Structures of ?-amyrin 68???-amyrin 69, euphol 70, and celastrol 71.Figure 23
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In summary: inflammation is a truly complex process and several different mediators are 
involved, which makes discovery of new anti-inflammatory compounds very challenging.
Assays generally involve extensive animal testing or in vitro experiments on several 
separate enzymes. Up to now, mainly natural triterpenes have been tested, and typically 
the assayed sets of compounds have included very few derivatives. Since the assays and 
targets vary greatly, and the number of the tested compounds is low, it is nearly 
impossible to find any meaningful SAR related to anti-inflammatory effects of 
triterpenoids. Only oleanolic acid derivatives have been studied extensively enough to 
conduct SAR data as addressed above.104 However, some individual compounds show 
enough inhibition of inflammation mediators to be good targets for further development.
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3 Aims of the study
The aim of the study was to modify functional groups of the betulin skeleton to improve 
the biological activities of the starting natural compounds betulin (1), betulinic acid (2)
and betulonic acid (3). In addition, the aim was to find betulin-derived compounds with 
high potency and good selectivity for further development.
The more specific aims of the study were
? to design and synthesize heterocycle-fused betulin derivatives which are more active 
against Leishmania donovani (I)
? to design and synthesize inhibitors of the serine hydrolase ?/?-hydrolase 12
(ABHD12) and to generate a pharmacophore model for ABHD12 inhibitors based on 
lupane-type triterpenoids (II)
? to design and synthesize anti-invasive betulin derivatives against prostate cancer cell 
models (III)
? to design and synthesize betulin derivatives with anti-inflammatory effects and study 
their effects in vitro and in vivo (IV)
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5 Results and discussion
5.1 Anti-leishmanial activity of betulin derivatives (I)
5.1.1 Synthesis of betulin derivatives for activity studies against Leishmania 
donovani
Previously our group had found that heterocyclic betulin derivatives possess promising
anti-leishmanial activity on L. donovani, which causes the most severe form of 
leishmaniasis.9,28 Based on those results, we wanted to further explore effects of different 
kinds of fused heterocyclic betulin derivatives with varying groups at C-28 on L. donovani
axenic amastigotes. Axenic amastigote assay has proven to be a quick, reliable and 
affordable screening method.123
It should be noted that none of the synthesis routes were optimized, because our 
objective was to produce sufficient amounts of the target compounds for biological 
testing. A detailed presentation of the materials, synthetic, and analytical methods can be 
found in the original Publication I and in the associated supporting information.
The natural product betulin (1) was used as a starting point for all syntheses. Betulin 
(1) was oxidized by Jones oxidation to betulonic acid (3), which was used as a versatile
synthesis intermediate (Figure 24). Even though Jones oxidation is described generally as
an easy way to convert primary alcohols to carboxylic acids in one step, starting from
betulin (1), extracting and purifying the resulting betulonic acid (3) was really laborious
process and the isolated yields remained low. A great amount of research has been done to 
find better yielding, less toxic, environmentally friendlier, cheaper, and more facile
methods for oxidizing betulin (1) into betulonic acid (3).124–126 Nevertheless, Jones 
oxidation remains as the most reliable method to prepare betulonic acid (3) from betulin
(1). The ketone carbonyl at C-3 of betulonic acid (3) was utilized in syntheses of A-ring 
fused heterocycles. Pyridine (72), pyrazine (73) and indole (74-76) derivatives were 
obtained from betulonic acid (3) in one step (Figure 24).
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Synthesis of indole and pyrazine derivatives of betulinic acid. Reagents and Figure 24
conditions: (a) Na2Cr2O7, H2SO4, H2O, acetone, rt, 21 h, 44%; (b) appropriate 
phenylhydrazine hydrochloride, acetic acid, reflux, 3 h, 21-42%; (c) 1,2-
ethylenediamine, sulphur, morpholine, reflux, 21 h, 68%; (d) propargylamine, 
Cu(I)Cl, ethanol, reflux, 17 h, 11%.
Next, betulonic acid (3) was converted into another useful synthesis intermediate, 2-
hydroxymethylene adduct (77), by the Claisen condensation with ethyl formate (Figure 
25). Refluxing compound 77 in acidic conditions with hydrazine hydrate gave the 
pyrazole derivative 78, and its analogous reaction with hydroxylamine hydrochloride 
yielded the isoxazole derivative 79.
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Synthesis of pyrazole and isoxazole derivatives of betulinic acid. Reagents and Figure 25
conditions: (a) ethyl formate, NaH, THF, rt, 16 h, 56%; (b) H2NNH2?H2O, p-TsOH,
toluene, 150 °C, 17 h, 80%; (c) H2NOH?HCl, acetic acid, reflux, 3 h, 68%.
A reaction between betulonic acid (3) and hydroxylamine hydrochloride produced an 
oxime derivative 80, which was converted in the presence of trifluoroacetic anhydride 
(TFAA) to the target 7-membered A-ring lactam (81) in the classical Beckmann 
rearrangement (Figure 26).
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Synthesis of lactam derivative of betulinic acid. Reagents and conditions: (a) Figure 26
H2NOH?HCl, pyridine, methanol, reflux, 16 h, 84%; (b) TFAA, DCM
(dichloromethane), rt, 20 h, 33%.
Refluxing betulin (1) in formic acid rearranges it into allobetulin (82; Figure 27).127 The 
oxidation of allobetulin into allobetulone works well by Jones oxidation. Indole 
derivatives of allobetulin (83, 84) were synthesized by the Fischer indole synthesis in the 
same fashion as described above for using betulonic acid (3) as a starting material. The 
compounds derived from allobetulin (82) and allobetulone are less soluble than the 
corresponding betulonic acid derivatives, which may complicate carrying out biological 
assays. This should be kept in mind when interpreting biological results, since lower 
activity may not result from different structural features, but the lower solubility of the test 
substances in the assay system. In any case, these compounds could help studying the 
significance of the C-28 carboxyl group.
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Synthesis of indole derivatives of allobetulin. Reagents and conditions: (a) formic Figure 27
acid, reflux, 45 min; 1 M KOH in ethanol, benzene, 30 min, 25%; (b) Na2Cr2O7,
H2SO4, H2O, acetone, rt, 21 h, 88%; (c) appropriate phenylhydrazine hydrochloride, 
acetic acid, reflux, 2 h, 19-57%.I
Based on the literature, the carboxyl group at C-28 appears to be important for most of the 
bioactivities betulin derivatives have been reported to possess. However, only a few 
different kind of variations have been made for the C-28 position of the lupane skeleton,
and a related comprehensive study with bioisosteres is still missing. The reason for the 
lack of such a study is probably the fact that it would require laborious multistep syntheses
when, in general, only simple one-step syntheses are used to derivatize natural 
compounds. However, a tiny step towards studying effects of different groups at C-28 was 
taken with a set of isoxazole derivatives of betulin. We synthesized isoxazole derivatives 
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of betulin with primary amide (85), acetoxy (86), hydroxy (87), and aldehyde (88) groups
at C-28 (Figure 28).
Compound 79 was first converted into the corresponding acyl chloride, which was 
treated with aqueous ammonia to obtain the primary amide 85. The primary hydroxy 
group of betulin 1 was protected as tetrahydropyranyl (THP) ether allowing a selective 
oxidation of the C-3 hydroxy group by pyridinium chlorochromate (PCC). In strongly 
acidic conditions of the subsequent isoxazole ring-forming step, the THP group was 
replaced with an acetoxy group. The subsequent deprotection and oxidation reactions gave
the hydroxy and aldehyde derivatives, respectively (Figure 28).
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C-28 modifications of the isoxazole derivative of betulonic acid. Reagents and Figure 28
conditions: a: Starting from 79: (I) oxalyl chloride, DCM, rt, 1 h; (II) 25% aqueous 
ammonia, CHCl3, rt, 30 min, yielding 85, quant. b: Starting from betulin (1):(I) 
pyridine p-toluenesulfonate, 3,4-dihydro-2H-pyran, DCM, rt, 18 h, 80%; (II) PCC, 
DCM, rt, overnight, 46%; (III) ethyl formate, NaH, THF, rt, 22 h, 52%; (IV) 
H2NOH?HCl, acetic acid, reflux, 4 h, yielding 86, quant.; c: Continuing from 86: p-
TsOH, methanol, reflux, 20 h, yielding 87, quant.; d: Continuing from 87: IBX, THF, 
DMSO, rt, 3.5 h, yielding 88, 51%.
Our modification studies of pyrazine derivatives comprised only C-28 primary amide (89)
and oxime groups (90; Figure 29). Compound 90 was obtained by oxidizing betulin (1) to 
betulonic aldehyde followed by the formation of a pyrazine ring, and finally the 
conversion of an aldehyde group to an oxime.
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C-28 modifications of a pyrazine derivative of betulonic acid. Reagents and Figure 29
conditions for 89: Starting from lupa-2,20(29)-dieno[2,3-b]pyrazin-28-oic acid (73):
(a) oxalyl chloride, DCM, rt, 3 h; (b) aqueous ammonia, DCM, rt, 1 h, quant.; for 90:
Starting from betulin (1): (a) PCC, DCM, rt, 1 h, 27%; (b) 1,2-ethylenediamine, 
sulfur, morpholine, reflux, 2.5 h, 17%; (c). H2NOH?HCl, pyridine/ethanol (1:3), 
reflux, 16 h, 77%.
In some studies, the corresponding compounds with an isopropenyl or isopropyl group at 
C-19 gave different activity results. To study whether the isoxazole derivatives of betulin 
follow a similar pattern, compound 91 was synthesized (Figure 30). Initially we had
serious troubles in our attempts to reduce the C-20 carbon-carbon double bond of 
betulonic acid (3). Reduction of the double bond worked fine with betulin (1) (in 
methanol/ THF 2:1) but, due to low yield of the following Jones oxidation, this route was 
not feasible. Next, reduction of the isopropenyl group was carried out for betulonic acid 
methyl ester and its carbon-carbon double bond was reduced successfully; but here we hit 
the wall with cleavage of the ester. When we used benzyl ester as the protecting group, we 
got a 1:1 mixture of starting material and hydrogenated product. The solvent used was 
changed from THF to ethyl acetate, resulting in the single desired product. Later, a similar
reduction was carried out for betulonic acid (3) in ethyl acetate, and even after prolonged 
reaction time, little bit of starting material was still present. Hence, using benzyl protection 
was the most practical route to obtain an isopropyl moiety at C-19. The subsequent
isoxazole synthesis worked equally well as before.
O
COOH a-d COOH
N
O3 91
Synthesis of isoxazole derivative of dihydrobetulinic acid. Reagents and conditions: Figure 30
(a) benzyl bromide, K2CO3, DMF, 55 °C, 22 h, 43%; (b) H2, 10% Pd/C, ethyl acetate,
rt, 72 h, quant.; (c) ethyl formate, NaH, THF, rt, 22 h, 56%; (d) H2NOH?HCl, acetic 
acid, reflux, 6 h, 90%.
Leishmania-human immunodeficiency virus (HIV) co-infections have been reported from 
35 endemic countries. This co-infection causes more severe forms of leishmaniasis which
are more difficult to treat, therefore those people infected have very high mortality rates.11
Keeping this in mind, we synthesized a known anti-HIV agent bevirimat, 3?-(3-carboxy-
3-methylbutanoyloxy)lup-20(29)-en-28-oic acid (92) to explore its effects on L. donovani 
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(Figure 31). Several different conditions, including microwave irradiation, different 
temperatures, solvents and catalysts were tried and eventually a method was found to 
produce a sufficient amount of compound 92 for biological tests.
HO
COOH
O
COOH
HO
O
O
O
COOH a b
9223
Synthesis of bevirimat. Reagents and conditions: (a) NaBH4, 2-propanol, rt; (b) 2,2-Figure 31
dimethylsuccinic anhydride, DIPEA (N,N-diisopropylethylamine), DMF 170 °C, 2 d, 
5%.
5.1.2 Biological profiling of the experimental set of betulin derivatives
against Leishmania donovani
Leishmanicidal activity of the compounds was assayed by alamarBlue viability assay on 
axenic amastigotes. Assays were started at 50 μM concentration following with an assay 
at 15 μM for compounds with more than 70% inhibition at 50 μM. The most potent 
derivatives were assayed at 5 μM concentration.
Among the isoxazole derivatives (78, 85-88, and 91) inhibition at higher 50 μM 
concentration varied a lot (Figure 32). However, all the compounds having higher activity
at 50 μM showed similar inhibition to each other at lower 15 μM concentration. All of 
them had lower activity than betulonic acid (3).
Average inhibition activity of triplicates of the tested compounds on axenic Figure 32
amastigotes of Leishmania donovani. Amphotericin B was tested at 1 μM as a 
positive control. *Compounds 2 and 78 precipitated at 50 μM.I
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Pyrazine derivatives 73 and 89 showed good inhibition even at lower concentrations. 
Interestingly, an exception to this trend was the pyrazine derivative with a C-28 oxime 
group (90); it had almost no activity at all, in contrast to the previous studies, where oxime 
derivatives showed good inhibition at 50 μM.28
Among the tested compounds, three of them, 73, 80, and 92, were found to have 
significant inhibition of parasite growth at 5 μM concentrations. On the other hand, 
compounds also showed slight THP-1 macrophage toxicity.
When comparing these results to our previous ones, some improvement can be seen. 
IC50 values of the three most active compounds in this study were 4 - 13 μM, whereas in
our earlier study these values varied in the range of 9 - 30 μM.9 However, in order to 
obtain more potent betulin derivatives against L. donovani, further optimization and 
improvement are clearly needed.
5.2 Betulin derivatives as serine hydrolase (ABHD)12 inhibitors 
(II)
ABHD12 is one of the enzymes hydrolyzing 2-AG, which is a natural ligand for 
cannabinoid receptors, i.e. an endocannabinoid.128 Mutations in the ABHD12 gene cause 
PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, cataract) disorder,
which is a neurodegenerative disease leading to cataract, hearing loss, and ataxia, to name
few symptoms.129 Since the crystal structure of ABHD12 is not known, developing new 
ligands is challenging. Abundant triterpenes serve as a good starting point for the 
discovery of new ABHD12 inhibitors, as they have shown several related activities.
Previously certain triterpene derivatives were found to inhibit human ABHD12 hydrolase 
activity reversibly. For example, pristimerin (9) has been shown to inhibit MAGL activity 
in vitro121,130?? ???? ?-amyrin (68?? ???? ?-amyrin (69) have been shown to reduce 
inflammatory and neuropathic hyperalgesia via cannabinoid receptors.116
5.2.1 Synthesis of C-28 and ring A-modified betulin derivatives
Previously our group had synthesized different kinds of ester and ether derivatives of 
betulinic acid.5 In addition to those compounds and derivatives for the Leishmania studies
described above, the carboxyl group of betulonic acid (3) was converted further into 
different amides (Figure 33). A detailed presentation of the materials, synthetic, and 
analytical methods can be found in the original Publication II and in the associated 
supporting information.
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Synthesis of amide derivatives of betulonic acid. Reagents and conditions: (a) (1) Figure 33
DCM, oxalyl chloride, rt, 5 h. (2) DCM, appropriate amine, rt, 19 h, yield 32-47%.
In the series of C-28-modified compounds, a pyrazine derivative with C-28 tertiary amide 
(96) was also synthesized (Figure 34). We wanted to make a compound with tertiary 
amino group at C-28; actually, we found that zinc acetate in the presence of
triethoxysilane had been reported to selectively reduce tertiary amides to amines, even in 
the presence of a ketone.131 Interestingly, and to our surprise, in the case of betulonic acid 
derivative 97 only the ketone was reduced. The amide stayed intact, resulting in
compound 98 as a product of the reaction.
N
ON
N
N
O
HO96 98
N
O
O 97
a b
Synthesis of compounds 96 and 98. Reagents and conditions: (a) 1,2-Figure 34
ethylenediamine, sulphur, morpholine, reflux, 2 h, yield 67%; (b) Zn(OAc)2,
triethoxysilane, THF, 40 °C, 1.5 h, yield 57%.
Since it is known that some triazole ureas inhibit serine hydrolases132, a 1,2,4-triazole 
derivative of betulonic acid (99) was synthesized (Figure 35). To avoid a hydrolytically 
labile urea structure, a triazole amide was synthesized instead.
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993
Synthesis of 1-(1H-1,2,4-triazol-1-yl)betulonone 99. Reagents and conditions: (a) Figure 35
1,1’-carbonyldi(1,2,4-triazole), THF, reflux, 20 h, yield 49%.
To diversify the structures of A ring-fused heterocycles, compound 100 was synthesized. 
Betulonic acid 3 was first oxidized to 101 which, in turn, was reduced to the diol 102. The 
formed diol was protected as an acetal to yield heterocyclic compound 100. Its tentative 
metabolite 102 was also tested. Moreover, 101 proved to be a useful intermediate for other 
syntheses.
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Synthesis of compound 100. Reagents and conditions: (a) t-BuOK, t-BuOH, 40 °C, Figure 36
air, 2 h, yield quant.; (b) NaBH4, ethanol, THF, 0 °C, 1.5 h, yield 74%; (c) pyridinium 
p-toluenesulfonate, 2,2-dimethoxypropane, rt, 22 h, yield 70%.
To study the effects of the position of nitrogen atoms in pyridine and pyrazine derivatives, 
a pyridine derivative possessing a nitrogen atom at C-2 was synthesized. First, the ketone
carbonyl at position C-3 had to be moved to C-2. After protecting the carboxyl group at C-
28 to yield 103, the C-3 ketone was converted into a diol 104. The diol 104 was converted 
to a tosylate at 30 °C. When the reaction temperature was increased to 60 °C, the tosylate 
participated in an elimination reaction that gave a mixture of two ketones (105 and 106).
In the literature, this method is described for betulin (1) only whereas, for the first time,
we used betulonic acid (3) as the starting compound.133 Despite several attempts, we were 
unable to separate the two ketones as benzyl esters (105 and 106) or carboxylic acids (107
and 108) before making the actual pyridine derivatives (109 and 72).
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Synthesis of the pyridine-fused lupane skeleton with the nitrogen atom in position C-Figure 37
2. Reagents and conditions: (a) Benzyl bromide, K2CO3, DMF, 55°C, overnight, 43%; 
(b) (i) t-BuOK, t-BuOH, 40 °C, air, 2 h, yield quant.; (ii) NaBH4, EtOH, THF, 0 °C,
1.5 h, yield 74%; (c) p-toluenesulfonyl chloride, dry pyridine, 30 °C for 6 h, 60 °C for 
18 h, yield 58%, mixture of compounds 105 and 106; (d) H2, 10% Pd/C, THF, 4.5 h, 
yield 80%, mixture of compounds 107 and 108; (e) propargylamine, CuCl2, ethanol,
reflux, 17 h, yield 21% of compound 109.
5.2.2 Structure-activity relationships of the tested compounds with ABHD12 
hydrolase
In our preliminary studies, ursolic acid (5) was unexpectedly recognized as a selective 
serine hydrolase ABHD12 inhibitor with insignificant effect on ABHD6 and MAGL.II
Encouraged by this finding, a set of triterpenoids was designed and tested. Starting with 
15 commercially available triterpenoids, it was demonstrated that the triterpene skeleton 
and the C-28 carboxyl group are important for human ABHD12 (hABHD12) inhibition.
Since oleanolic (4), ursolic (5) and betulinic acid (2) had only minor differences in their 
inhibitory activities, it was concluded that their characteristic substitution pattern and the 
size of ring E have no effect on hABHD12 inhibition; so betulinic acid derivatives were 
chosen for further studies. Structures of all the tested compounds can be found in 
Publication II and in the Supplemental Material of Publication II.
A series of betulinic acid derivatives was used to study further structural features 
needed for hABHD12 inhibition. The necessity of a carboxyl group at C-28 was 
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confirmed by testing C-28 aldehydes (88 and 110), esters (113-115, and 118), ether (112), 
and amides (93-95, 98), which showed only moderate to no potency (Figure 38). In 
addition, changing the carboxyl group to an oxime (111) lowered the potency (IC50 6.5
μM). Furthermore, potency was lowered when the C-3 hydroxy group of betulinic acid (2)
was replaced with an oxime group (80; IC50 12.0 μM). Finally, compound 117 possessing 
oxime groups at both C-3 and C-28 positions had enhanced potency (IC50 4.0 μM), but not 
at the same level as betulinic acid (2; IC50 2.5 μM).
Structures and inhibition activities of the tested aldehyde, ester, ether, amide and Figure 38
oxime derivatives of betulin in hABHD12-HEK293 lysates.II
The effects of ring A modification were also studied (Figure 39). Adding a hydroxy group 
to C-2 showed similar inhibition to the parent compound betulinic acid (2). All ring A-
fused heterocycles showed good inhibition. Changing the ring A into a lactam ring or 
adding a 2,2-dimethyldioxolane moiety showed modest inhibition. Inhibition was 
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improved slightly by fusing a pyridine ring with the nitrogen atom at C-3. Inhibition was 
improved even further when another nitrogen atom was introduced to the fused ring at the 
C-2 position, i.e. pyrazine ring. The importance of the carboxyl group at C-28 was also 
seen here, as inhibition decreased significantly when it was replaced with a primary or 
tertiary amide moiety. The fused pyridine ring with a nitrogen atom at C-2 showed only 
very low inhibition. Since the ring A-fused isoxazole derivative showed low inhibition as 
well, it seems that a hydrogen bond donor or acceptor at the C-3 position is important for 
the enzymatic inhibition.
Fusing an indole or a pyrazole ring to the lupane skeleton improved inhibition, the 
indole derivative (74) being the most active compound with an IC50 value of 0.9 μM
(Figure 39). The inhibition potencies of indole derivatives were higher than those
determined for the natural compounds maslinic acid (6) and oleanolic acid (4). Pyrazole 
derivative (78) was able to inhibit the enzyme at the same level as these natural products. 
The importance of the C-28 carboxyl group was observed with the indole derivative too, 
since inhibition was completely lost for the indole derivative of allobetulin when assayed.
Structures of the ring A-modified betulinic acid derivatives and their inhibition Figure 39
activities in hABHD12-HEK293 lysates.II
Fusing urazole ring with varying substituents to the lupane skeleton of betulin decreased
the inhibition of serine hydrolase ABHD12 (Figure 40). Ester groups at C-28 of betulin 
were not tolerated either. The inhibition activities of selected urazole derivatives are 
presented in Figure 40.
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Structures of urazole derivatives assayed and inhibition activities in hABHD12-Figure 40
HEK293 lysates.II
Dihydrobetulonic acid (137, Figure 41) showed improved hABHD12-HEK293 lysate 
inhibition (1.6 μM) compared to betulonic acid (3; 3.3 μM). It is noteworthy that no other 
targets among the metabolic serine hydrolases were found for compound 137.
O
OH
O
137
The structure of the dihydrobetulonic acid 137.Figure 41
31
The IC50 values of the most active compounds are presented in Figure 42. Compound 74
was the most active. It showed improved inhibition compared to any of the natural 
products tested. Compounds 75 and 78 were almost as potent and showed the same level 
of inhibition as the natural compounds.
IC50 values of the most active triterpenoids tested in hABHD12-HEK293 lysates. Data Figure 42
are mean of three independent experiments. *n=2
Important features for inhibitory activity against serine hydrolase ABHD12 are 
summarized in Figure 43. The shape of a triterpene skeleton plays an important role as 
additional double bonds, which change the shape of the molecular skeleton, resulted in no 
inhibition (compound 32 and celastrol 71). The carboxyl group at C-28 is important, as all
its modifications lead to lower inhibition. A small hydrophobic substituent is needed at C-
4, since asiatic acid and hederagenin showed no inhibition. A hydrogen bond donor or 
acceptor is required at C-3 for high inhibitory activity. This was shown with pyridine and 
pyrazine as well as with pyrazole and isoxazole derivatives of betulinic acid.
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The core structure of the triterpenoid skeleton can be recognized by many proteins and 
therefore triterpenoids have shown activity with many targets. However, the triterpenoids
assayed in this study displayed no activity on other established targets of the 
endocannabinoid system, such as ABHD6, MAGL, fatty acid amide hydrolase (FAAH) or 
the cannabinoid receptors CB1 and CB2. When the structure of betulinic acid (2) was 
superimposed with those of the in vivo substrate LPS and irreversible inhibitor 
tetrahydrolipstatin (THL), striking similarities in topology, dimensions, and distance as
well as orientation of the functional groups were found (Figure 44).
LPS (in A orange carbons), the in vivo substrate of ABHD12, and THL (in B green Figure 44
carbons), the irreversible inhibitor of ABHD12, superimposed with betulinic acid (2)
(grey carbons). The carboxyl group of LPS and the formyl group of THL align with 
the carboxyl group of betulinic acid (2; dark grey circle). The ester carbonyl of LPS 
and the lactone carbonyl of THL align with the hydroxy group of betulinic acid (2;
light grey circle). LPS and THL were modelled in an extended conformation and the 
hydrocarbon chains have been partially faded. Reprinted from II.
Sixty-eight triterpenoids were tested as ABHD12 inhibitors, and 18 compounds were 
classified as active. Based on the activities of these compounds, a pharmacophore model 
was constructed with 14 distinct pharmacophoric features (Figure 45).
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Pharmacophoric features for binding of triterpenes to ABHD12. Green: hydrophobic Figure 45
site, magenta: acceptor site, cyan: donor site, gray cage: ligand shape constraint. In 
B the best solution for the alignment of the most active compound (74) is presented. 
Reprinted from II.
In conclusion, ABHD12 inhibiting natural compounds and their derivatives were reported.
The best compounds inhibited hABHD12 fully with IC50 values in the submicromolar 
range. The compounds had no effect on other endocannabinoid hydrolases or cannabinoid 
receptors. The triterpenoids showed selective inhibition towards ABHD12. With the SAR 
analysis, important features for ABHD12 inhibition were determined. The first 
pharmacophore model was developed, based on those results.
5.3. Betulin derivatives active against prostate cancer cells (III)
5.3.1 Synthesis of betulin derivatives active against prostate cancer cells
The set of natural triterpenoids and their semisynthetic derivatives described above were 
tested against two prostate cancer cell lines PC-3 and LNCaP. In addition to those 
compounds, one more compound was synthesized to include a nitrile substituent at the C-
28 position. A detailed presentation of the materials, synthetic, and analytical methods can 
be found in the original Publication III and in the associated supporting information.
Starting from the ring A-fused pyrazine derivative of betulonic acid 73, the C-28 carboxyl 
group was converted into a nitrile group via a primary amide (Figure 46).
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Synthesis of compound 138. Reagents and conditions: (a) cyanuric chloride, DMF, 0Figure 46
°C, 1 h, yield 84%.
Compound 139 (Figure 47) was synthesized in same manner as described earlier for 
compounds 93-95. Compound 140 was obtained from the isoxazole derivative 79 by
cleaving the isoxazole ring with KOH in methanol.
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Structures of the compounds 139 and 140.Figure 47
5.3.2 Biological profiling of the betulin derivatives on prostate cancer cells
Betulinic acid (2) has been identified as an inducer of apoptosis in melanoma cells (cell 
lines MEL-1, MEL-2 and MEL-4).10 In addition, betulin (1) has been found to block 
invasion in brain and lung cancer cells (C6, and A549, respectively).134 Here 
antineoplastic and anti-invasive properties of these compounds and their synthetic
derivatives on prostate cancer cell lines (PC-3 and LNCaP) were studied. Starting with 
high-throughput screening, cancer-specific compounds were identified and a set of related 
compounds was synthesized. Modifications were made to the A ring and C-28, and these 
new compounds were also used in ABHD12 studies (vide supra).
Biological assays started with high-throughput screening using 2D (2-dimensional)
cell cultures. The cell lines used were EP156T (non-transformed prostate epithelium), 
LNCaP (androgen sensitive prostate cancer) and PC-3 (castration-resistant invasive 
prostate cancer). The subsequent studies continued with 3D (3-dimensional) setting for
specific anti-invasive properties. To interpret the complex image data obtained, statistical 
analyses were performed. Using measures of area, complexity and area of dead cells from 
PC-3 cultures, a dendrogram with hierarchical clustering was generated (Figure 48). The 
dendrogram has two main branches: one cluster includes the most potent anti-proliferative 
and anti-invasive compounds (in blue); the other contains weak (in green) and non-
effective (in grey) compounds.
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Hierarchical clustering using three morphological parameters (area, complexity and Figure 48
the number of dead cells) derived from PC-3 organoids. Anti-invasive compounds are 
presented in blue, compounds with low activity are in green, and non-active 
compounds are in grey. Modified from III.
Betulinic acid (2) and betulonic acid (3) did not show significant anti-invasive effects. 
However, betulonic acid derivatives with an isopropyl group at C-19 (137) instead of an 
isopropenyl group showed a strong anti-invasive effect and growth inhibition. A similar 
effect, but milder, was seen for two isoxazole derivatives only differing in structure at C-
19; both of them showed strong growth inhibition and anti-invasive effects at low 
concentrations (79 1.0 μM and 91 300 nM). The importance of the C-28 carboxyl group 
was seen among the set of isoxazole derivatives with varying groups at C-28. Isoxazole 
derivatives having primary amide (85), acetoxy (86), hydroxy (87), or formyl (88) groups
at C-28 had insignificant effects on the invasive phenotype. The same trend was also seen 
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with betulonic acid derivatives: when the C-28 carboxyl group was replaced with a
secondary (93) or tertiary amide (94, 95, and 139), activity was lost.
When the isoxazole ring of 79 was changed to a pyrazole, the resulting compound 78
was even more potent and specifically anti-invasive. The pyrazine derivative of betulinic 
acid (73) had a strong anti-invasive effect without any growth inhibition. Surprisingly, a
primary amide moiety at C-28 (89) did not decrease the anti-invasive effect level. On the 
other hand, pyrazine derivatives bearing tertiary amide or nitrile groups at C-28 showed no
inhibition. Interestingly, pyridine derivatives having nitrogen at C-2 or C-3 were anti-
invasive at significantly lower concentrations than the pyrazine derivative. This might be 
due to their higher lipophilicity compared to pyrazine derivative.
In order to find out which were the most potent cytotoxic compounds instead of being 
anti-invasive, inhibition of proliferation and induction of cell death was studied. In PC-3
cells, most compounds did not show noticeable effects on proliferation at low 
concentrations (<10 μM). In LNCaP cells, growth inhibition and cytotoxicity started at 
lower concentration (3 μM); and in Ep156T cells, cytotoxicity was observed at even lower 
concentrations (0.3 – 1 μM). The compounds did not induce cell death specifically in PC-
3 or LNCaP cells at lower concentrations than 30 μM.
Additionally, it was confirmed by kinase phosphorylation profiling that compounds 79
and 109 do not primarily affect cell cycle progression or mitosis. They are cytotoxic only 
at high concentrations. At low (nanomolar) concentrations they promote anti-invasive 
effects. These compounds disrupt actin cytoskeleton organization, which could be 
observed from the corkscrew-like phenotype of the filamentous actin (Figure 49). This 
may be linked to efficient suppression of the invasive properties of PC-3 cells.
Confocal microscope-captured 3D morphologies of prostate spheroids exposed to Figure 49
compounds 79 and 109. The actin cytoskeleton is stained green, nuclei with red.
Reprinted from III.
Chemical structures of the compounds showing the most potent anti-invasive effects on 
PC-3 cells are presented in Figure 50. These compounds did not show noticeable effects
with other cell lines. Even though most of them showed growth inhibition in all cell lines 
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at higher (> 1 μM) concentrations, they may act as specific inhibitors of invasion and 
motility at lower concentrations.
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Structures of the compounds most active against prostate cancer cell line PC-3.IIIFigure 50
The important features for anti-invasive effects are summarized in Figure 51. Based on 
these results, the carboxyl group at C-28 is important for activity. A single bond at C-19 
and a hydrogen bond donor at C-2’ of the A ring-fused heterocycle seem to improve 
activity considerably. Extensions of the A ring-fused heterocycle were not tolerated.
O
OH Carboxyl group
improves activity
A single bond
improves activity
Hydrogen bond
donor might
enhance activity
HN
N
Extensions not
tolerated
Features needed for anti-invasive effects on the PC-3 prostate cancer cell lineFigure 51
compared to compound 78.
5.4 Anti-inflammatory effects of betulin derivatives (IV)
Encouraged by the earlier studies showing betulin (1) and betulinic acid (2) to possess 
anti-inflammatory properties97,7 we wanted to explore the effects of heterocyclic betulin 
derivatives on inflammation as well. The mechanism of action behind the effects was also 
studied. Chemical structures of the compounds tested are given in Figures 52 and 53.
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Structures of the betulin derivatives tested for their ability to inhibit LPS-induced Figure 52
iNOS protein expression.IV
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Structures of the betulin derivatives tested for their ability to inhibit LPS-induced Figure 53
iNOS protein expression (cont’d).IV
The effects of the set of compounds on the expression of the inflammatory enzymes such 
as iNOS and COX-2, on the production of NO, interleukin-6 (IL-6), and chemotactic 
factor monocyte chemotactic protein-1 (MCP-1) were studied. The results are presented in 
Figure 54. Interestingly, some of the compounds, especially betulin (1), promoted the 
expression of inflammatory enzymes and the production of inflammation transmitters.
However, compounds with inhibitory effects were found among the set as well. 
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Previously, ursolic acid (5) was shown to stimulate NO production, whereas its derivatives 
showed inhibitory activity.100
Inhibiting effects of betulin derivatives on NO, iNOS, COX-2, IL-6, and MCP-1 in Figure 54
J774 macrophages.IV
Ten of the nineteen compounds tested showed over 50% inhibition of iNOS protein 
expression at 10 μM concentration. Three of them (73, 85, and 111) decreased iNOS 
protein expression more than 90% at 10 μM concentration, and they were selected for 
further dose-response studies. All of them gave clear dose-response effects, and their IC50
values varied between 0.3-3 μM. None of the compounds showed activity in iNOS mRNA 
assays, suggesting the effect of betulin derivatives on iNOS protein expression could be 
mediated through post-transcriptional mechanisms.
Three of the compounds (78, 88, and 141) inhibited COX-2 protein expression 
significantly at 10 μM concentration. Compound 141 was the most potent COX-2
inhibitor with a 57% decrease of COX-2 protein expression. In LPS-induced NO 
production assays, five compounds (1, 3, 73, 91, and 111) stood out by reducing NO 
production over 50% at the 10 μM concentration used.
Compound 78 was the most effective compound in both IL-6 production and MCP-1
production assays with 60% and 70% inhibitions, respectively. In further studies, it was 
shown that compound 78 suppresses iNOS and IL-6 mRNA levels significantly. These in 
vitro studies correlated with in vivo studies, as compound 78 significantly reduced 
carrageenan-induced paw inflammation in mice (Figure 55).
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The effect of the compound 78 on carrageenan-induced paw inflammation model in Figure 55
mice. Compound 78 (10 mg/kg) or dexamethasone (2 mg/kg) or saline were 
administered i.p. 2 h prior to carrageenan (1.5%) was injected into the paw. The 
edema was measured 3 h and 6 h after intraplantar injection and was compared to 
the basal level. Results are expressed as mean ± SEM, n=6-12, ***p<0.001 as 
compared to mice without drug treatment. The contralateral control paw injected 
with saline developed no measurable edema.IV
The assayed betulin derivatives showed improved anti-inflammatory activity compared to 
natural triterpenoid betulin (1). The betulin derivatives 11, 73, 78, and 85 showed 
inhibition of iNOS expression in vitro. The anti-inflammatory properties of compound 78
also correlated with those in vivo. To make further conclusions regarding the SARs, a
wider and more diverse set of compounds should be tested. However, compound 78 could 
serve as a starting point for drug development.
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6 Summary and conclusions
Betulin (1) is an abundant side product of the forestry industry without any meaningful 
use at the moment. Modifying betulin (1) chemically could increase its value as a fine 
chemical. In this work, betulin (1) was modified in order to produce suitable compounds 
for pharmaceutical applications. A set of fused heterocyclic derivatives of betulin was 
synthesized and SAR studies were conducted against leishmaniasis-causing protozoan 
parasites, ABHD12 serine hydrolase enzyme, prostate cancer cell lines and inflammation
factors.
Among the tested heterocyclic compounds, inhibitory activity against L. donovani was 
shown. Compared to the previous results of our group9, some progress was made. 
However, the compounds produced were not active enough to justify further, more 
advanced stages of testing. If more potent betulin derivatives against L. donovani are to be 
found, further optimization work is needed.
ABHD12 was only discovered a few years ago and little is known about its structure. 
Due to the lack of a crystal structure, all information about its substrates are useful.
Among the tested compounds, heterocyclic betulin derivatives were found to fully inhibit 
hABHD12 with IC50 values in the submicromolar range. The compounds proved to be 
selective inhibitors towards ABHD12 without any effect on other endocannabinoid 
hydrolases or cannabinoid receptors. The first pharmacophore model for ABHD12 was 
developed, based on our SAR studies.
Some of the tested heterocyclic betulin derivatives showed anti-invasive activity in 
PC-3 cells, even at nanomolar concentrations, with minimal cytotoxicity. Our results show 
that betulin derivatives are a good starting point for discovery of more selective and less 
toxic treatments for metastatic cancers.
The fused heterocyclic derivatives of betulinic acid showed improved anti-
inflammatory activity compared to the natural products betulin (1) or betulinic acid (2).
The results were consistent in vitro and in vivo. Inflammation involves complex signaling 
cascades and many different mediators, which makes discovery of new anti-inflammatory 
compounds really challenging. In order to get SAR data and more potent anti-
inflammatory agents, a wider set of betulin derivatives should be assayed. However, our 
compound 78 could work as a starting point for further development.
In this work, a number of new betulin derivatives was synthesized, and their biological 
activities with selected targets were tested. Some really good and unexpected bioactivities 
were found, even though more research is needed to get potent lead compounds. Other 
properties of the triterpenoids, such as lipophilicity and cytotoxicity, should also be taken 
in consideration when planning further development. One point proven herein is that 
natural products are still a valid starting point for modern drug discovery.
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